EyePoint Pharmaceuticals: Mizuho Sees 102% Price Potential Referencing DURAVYU, the Competitive Position, and Strong Liquidity Base!
Reading Time: 5 minutes
Strategic Kickoff to 2026 EyePoint Pharmaceuticals (EYPT) has begun 2026 with a clear message to the capital markets, particularly emphasized by the corporate update on January 7 and the presentation at the 44th J.P. Morgan Healthcare Conference. From the corporation's perspective, 2026 is a pivotal transition year in which years of research on the proprietary Durasert technology are expected to translate into tangible clinical results. The management underscores the transformation from a pure development company to a potential market leader...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
